NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07 2024 - 4:01PM
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or
the “Company”), a late-stage, clinical biopharmaceutical company
developing oral, non-statin medicines for patients at risk of
cardiovascular disease (“CVD”) with elevated low-density
lipoprotein cholesterol (“LDL-C”), for whom existing therapies are
not sufficiently effective or well-tolerated, today announced that
the Compensation Committee of NewAmsterdam’s Board of Directors
approved the grant of inducement share options covering an
aggregate of 90,000 of NewAmsterdam’s ordinary shares to five
non-executive new hires. The share options were granted as an
inducement material to the employees’ acceptance of employment with
NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024
Inducement Plan (the “2024 Inducement Plan”) and in accordance with
Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
$18.92, which represents the closing market price on the Nasdaq
Stock Market of the Company’s ordinary shares on, June 3, 2024, the
grant date. The shares subject to the options will vest over four
years, with 25% of the shares vesting on the one-year anniversary
of the applicable vesting commencement date and the balance of the
shares vesting in a series of 36 equal monthly installments
thereafter, subject to each employee’s continued service with
NewAmsterdam on such vesting dates. The options are subject to the
terms and conditions of the 2024 Inducement Plan and the terms and
conditions of an option award agreement covering the grant.
About NewAmsterdamNewAmsterdam Pharma (Nasdaq:
NAMS) is a late-stage biopharmaceutical company whose mission is to
improve patient care in populations with metabolic diseases where
currently approved therapies have not been adequate or well
tolerated. We seek to fill a significant unmet need for a safe,
well-tolerated and convenient LDL-lowering therapy. In multiple
phase 3 studies, NewAmsterdam is investigating obicetrapib, an
oral, low-dose and once-daily CETP inhibitor, alone or as a
fixed-dose combination with ezetimibe, as LDL-C lowering therapies
to be used as an adjunct to statin therapy for patients at risk of
CVD with elevated LDL-C, for whom existing therapies are not
sufficiently effective or well tolerated.
Company ContactMatthew PhilippeP:
1-917-882-7512matthew.philippe@newamsterdampharma.com
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Historical Stock Chart
From Jul 2024 to Aug 2024
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Historical Stock Chart
From Aug 2023 to Aug 2024